JACC:这一不起眼的坏“血脂”,居然增加6成中风风险!

2021-07-27 MedSci原创 MedSci原创

从人类遗传学的观察和因果关系来看,高LP(a)水平与缺血性中风风险增加相关。

1963年,遗传学家Kare Berg发现了一种与低密度脂蛋白胆固醇(LDL-C)相似的脂蛋白颗粒,将其命名为脂蛋白(a)(LPa)。在过去的十年里,一些大型的当代研究重燃了这种兴趣,他们发现无论是从观察上还是从人类遗传学的因果关系上,高LPa水平与心肌梗死和主动脉瓣狭窄的风险增加有关。

LPa的血浆水平主要由LPA基因的变异在遗传上决定,并且在普通人群中水平差异很大,大约20%的人具有高水平,并且有些达到了极端的程度。LPa具有几种可能致病的特性;它由一种含有脂蛋白的载脂蛋白B(aPOB)组成,该脂蛋白可通过动脉壁胆固醇沉积直接促进动脉粥样硬化。

此外,脂蛋白具有共价结合的载脂蛋白A(aPOA)分子,其重复序列类似于纤溶酶原,从而潜在地与纤溶酶原竞争内皮细胞上的受体,导致纤溶酶形成减少和有利于血栓形成的延迟凝块溶解;LPa与低出血风险相关的事实也支持上述观点。

目前的研究已经确定了中风发展的几个危险因素:如年龄、男性和亚洲血统;与生活方式相关的危险因素,如吸烟、肥胖、饮酒和高脂血症;以及医疗状况,如高血压、糖尿病、心房颤动、既往TIA发作和心肌梗死。

在以前的研究中已经研究了高LPa与缺血性和出血性卒中风险的关系;但结果相互矛盾。为此,来自丹麦哥本哈根哥本哈根大学赫勒夫和根托弗特医院的血管专家从人类遗传学的角度观察和推断LPa是否与缺血性卒中的高风险相关,结果发表在JACC杂志上。

该研究包括来自哥本哈根普通人群研究的49699名个体和来自哥本哈根城市心脏研究的10813名个体,测量了血浆LPa、LPA基因kringle Ⅳ 2型(KIV-2)重复拷贝数,和LPA rs10455872。缺血性卒中的终点是从丹麦国家健康登记处确定的。

根据脂蛋白(a)水平进行多变量调整的缺血性卒中危险比

结果显示,与LP(a)水平< 10 mg/dl (<18 nmol/l:第1至第50百分位)的个体相比,对于LP(a)> 93mg/dl (>199 nmol/L:第96至第100百分位)的个体,缺血性卒中的风险增加60%(多变量调整OR=1.60,95%CI:1.24-2.05)。

50 mg/dl (105 nmol/l)LP(a)水平患者缺血性卒中风险则高20%(OR=1.20,95%CI:1.13-1.28),而KIV-2重复次数的相应年龄和性别调整遗传风险比为1.20 (95%CI:1.02至1.43),rs10455872为1.27 (95%CI:1.06-1.43)。

不同脂蛋白(a)水平类别中缺血性卒中的累积发生率

此外,在高血压和LP(a)水平> 93 mg/dl (>199 nmol/l:第96至100百分位)的70岁以上吸烟者中,缺血性卒中的10年最高绝对风险为17%。在哥本哈根城市心脏研究中,高水平脂蛋白(a)的风险估计是同一个方向,但没有达到统计学意义。

由此可见,从人类遗传学的观察和因果关系来看,高LP(a)水平与缺血性中风风险增加相关。

 

参考文献:

Langsted A, Nordestgaard BG, Kamstrup PR. Elevated Lipoprotein(a) and Risk of Ischemic Stroke. J Am Coll Cardiol. 2019 Jul 9;74(1):54-66.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1739723, encodeId=4aca1e39723f9, content=<a href='/topic/show?id=ff0c2262459' target=_blank style='color:#2F92EE;'>#中风风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22624, encryptionId=ff0c2262459, topicName=中风风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ba34554146, createdName=1249898am26暂无昵称, createdTime=Wed May 25 18:45:05 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854968, encodeId=75a41854968ed, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 09 14:45:05 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326836, encodeId=f3f3132683661, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jul 29 11:45:05 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046098, encodeId=29a4104609836, content=中风是俗称,应该称为缺血性卒中吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Tue Jul 27 23:45:05 CST 2021, time=2021-07-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1739723, encodeId=4aca1e39723f9, content=<a href='/topic/show?id=ff0c2262459' target=_blank style='color:#2F92EE;'>#中风风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22624, encryptionId=ff0c2262459, topicName=中风风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ba34554146, createdName=1249898am26暂无昵称, createdTime=Wed May 25 18:45:05 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854968, encodeId=75a41854968ed, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 09 14:45:05 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326836, encodeId=f3f3132683661, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jul 29 11:45:05 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046098, encodeId=29a4104609836, content=中风是俗称,应该称为缺血性卒中吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Tue Jul 27 23:45:05 CST 2021, time=2021-07-27, status=1, ipAttribution=)]
    2021-09-09 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1739723, encodeId=4aca1e39723f9, content=<a href='/topic/show?id=ff0c2262459' target=_blank style='color:#2F92EE;'>#中风风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22624, encryptionId=ff0c2262459, topicName=中风风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ba34554146, createdName=1249898am26暂无昵称, createdTime=Wed May 25 18:45:05 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854968, encodeId=75a41854968ed, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 09 14:45:05 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326836, encodeId=f3f3132683661, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jul 29 11:45:05 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046098, encodeId=29a4104609836, content=中风是俗称,应该称为缺血性卒中吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Tue Jul 27 23:45:05 CST 2021, time=2021-07-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1739723, encodeId=4aca1e39723f9, content=<a href='/topic/show?id=ff0c2262459' target=_blank style='color:#2F92EE;'>#中风风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22624, encryptionId=ff0c2262459, topicName=中风风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ba34554146, createdName=1249898am26暂无昵称, createdTime=Wed May 25 18:45:05 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854968, encodeId=75a41854968ed, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 09 14:45:05 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326836, encodeId=f3f3132683661, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jul 29 11:45:05 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046098, encodeId=29a4104609836, content=中风是俗称,应该称为缺血性卒中吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Tue Jul 27 23:45:05 CST 2021, time=2021-07-27, status=1, ipAttribution=)]
    2021-07-27 guging

    中风是俗称,应该称为缺血性卒中吧

    0

拓展阅读

NEJM:小干扰RNAOlpasiran可显著降低冠心病患者的脂蛋白(a)水平

Olpasiran治疗显著降低了动脉粥样硬化性心血管疾病患者的脂蛋白(a)水平

JACC:新晋“坏”血脂LPa升高居然会增加心房颤动的风险

Lp(a)是房颤发展过程中的一个潜在的因果媒介,这表明Lp(a)的影响延伸至整个心肌组织。

JAMA:这一增加6成中风风险的坏“血脂”,终于有针对它的siRNA可以用了!

siRNA SLN360安全有效,并观察到血浆LPa浓度的剂量依赖性降低。

JACC:新型降脂药培拉卡森对脂蛋白(a)胆固醇和LDL-C的影响

脂蛋白(a)[Lp(a)]自发现以来约60年,现在被认为是心血管疾病的一个遗传的、独立的、可能是因果关系的危险因素。

JACC:脂蛋白(a)和冠脉钙化与动脉粥样硬化心血管风险的独立相关性

脂蛋白(a) 和冠状动脉钙化评分与动脉粥样硬化性心血管疾病的风险独立相关

血脂检查单中不起眼的它,竟与早期、晚期、总体前列腺癌发生风险升高都扯上关系?

PLOS Medicine:脂蛋白A和其他脂质与前列腺癌风险的关系:一项多变量孟德尔随机化研究